Bayer AG (XSWX:BAYN) Cash Flow from Financing: CHF-1,987 Mil (TTM As of Mar. 2026)


XSWX:BAYN Bayer AG XSWX:BAYN
35 GF Score
Price CHF48.69
GF Value CHF24.98
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bayer AG Cash Flow from Financing?

Bayer AG XSWX:BAYN +2.01% 35 Cash Flow from Financing is CHF-1,987 Mil as of Mar. 2026. GuruFocus rates XSWX:BAYN with a GF Score™ of 35/100 and a GF Value™ of CHF24.98 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2026, Bayer AG paid CHF0 Mil more to buy back shares than it received from issuing new shares. It received CHF664 Mil from issuing more debt. It paid CHF0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received CHF0 Mil from paying cash dividends to shareholders. It spent CHF184 Mil on other financial activities. In all, Bayer AG earned CHF481 Mil on financial activities for the three months ended in Mar. 2026.


Bayer AG  (XSWX:BAYN) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Bayer AG's issuance of stock for the three months ended in Mar. 2026 was CHF0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Bayer AG's repurchase of stock for the three months ended in Mar. 2026 was CHF0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Bayer AG's net issuance of debt for the three months ended in Mar. 2026 was CHF664 Mil. Bayer AG received CHF664 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Bayer AG's net issuance of preferred for the three months ended in Mar. 2026 was CHF0 Mil. Bayer AG paid CHF0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Bayer AG's cash flow for dividends for the three months ended in Mar. 2026 was CHF0 Mil. Bayer AG received CHF0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Bayer AG's other financing for the three months ended in Mar. 2026 was CHF-184 Mil. Bayer AG spent CHF184 Mil on other financial activities.


Bayer AG Cash Flow from Financing Related Terms


Bayer AG Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Bayer AG's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Cash Flow from Financing Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,874.63 -4,164.57 -640.35 -6,701.47 -3,624.31

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,185.46 -452.09 682.10 -2,697.70 480.57
XSWX:BAYN
35GF Score
Bayer AG XSWX:BAYN
Cash Flow from Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Bayer AG's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:

Bayer AG's Cash from Financing for the quarter that ended in Mar. 2026 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1,987 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of CHF-1,987 Mil mean?
Bayer AG (XSWX:BAYN) has a Cash Flow from Financing of CHF-1,987 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Bayer AG and its competitors.
Is Bayer AG's Cash Flow from Financing too high?
Bayer AG's current Cash Flow from Financing is CHF-1,987 Mil. Overall, Bayer AG has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Cash Flow from Financing compare to LLY and JNJ?
Bayer AG's Cash Flow from Financing of CHF-1,987 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Bayer AG and its competitors. Bayer AG's current Cash Flow from Financing is CHF-1,987 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (XSWX:BAYN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF24.98, compared to a current price of CHF48.69 — trading 94.9% above its estimated fair value. The current Cash Flow from Financing is CHF-1,987 Mil. Bayer AG's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Bayer AG (XSWX:BAYN), the current Cash Flow from Financing is CHF-1,987 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (XSWX:BAYN) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of CHF48.69 is trading 94.9% above its estimated GF Value™ of CHF24.98. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for XSWX:BAYN:

  • Cash Flow from Financing: CHF-1,987 Mil
  • GF Value™: CHF24.98 vs. price of CHF48.69 (94.9% above fair value)
  • GF Score™: 35/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BAYN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
35GF Score

Get the complete analysis for XSWX:BAYN

Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF48.69
Price
CHF24.98
GF Value